SCHEMBL6538725

SCHEMBL6538725

O=C(CNC(=O)OCc1ccccc1)On1nnc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.47
▸ LMNA P02545 1/20 0.46
▸ SIRT2 Q8IXJ6 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ TPSAB1 Q15661 1/20 0.45
▸ TPSD1 Q9BZJ3 1/20 0.45
▸ TPSG1 Q9NRR2 1/20 0.45
▸ BRD4 O60885 1/20 0.45
▸ HDAC3 O15379 2/20 0.44
▸ HDAC4 P56524 2/20 0.44
▸ HDAC1 Q13547 2/20 0.44
▸ HDAC7 Q8WUI4 2/20 0.44
▸ HDAC2 Q92769 2/20 0.44
▸ HDAC10 Q969S8 2/20 0.44
▸ HDAC11 Q96DB2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538945 0.88 HTT (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL3692447 0.84 HTT (0.53) NPC1RAB9ASMN1; SMN2LMNATPSAB1
SCHEMBL8092305 0.83 HDAC3 (0.55) NPC1RAB9ASMN1; SMN2ALDH1A1SIRT2
SCHEMBL5000788 0.83 NPC1 (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1SIRT2
SCHEMBL23388379 0.83 ASAH1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL10299926 0.78 SIRT2 (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1SIRT2
SCHEMBL6860969 0.78 KMT2A (0.47) SIRT2KMT2AHDAC3HDAC4HDAC1
SCHEMBL14441724 0.78 HDAC3 (0.54) NPC1RAB9ASMN1; SMN2ALDH1A1SIRT2
SCHEMBL14435181 0.78 CTSL (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL10081124 0.77 LMNA (0.63) SMN1; SMN2ALDH1A1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 — — US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 — — US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 — — EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB NPC1 1562/4885RAB9A 943/4885SMN1; SMN2 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback